ABSTRACT
This guidance provides recommendations for sponsors of investigational new drug applications (INDs), new drug applications (NDAs), abbreviated new drug applications (ANDAs), and supplements to these applications that wish to request a waiver of
in vivo
bioavailability (BA) or bioequivalence (BE) studies for immediate release (IR) solid oral dosage forms. These waivers apply to:
1. Subsequent
in vivo
BA or BE studies of formulations after the initial establishment of the
in vivo
BA of IR dosage forms during the IND period
In vivo
BE studies of IR dosage forms in ANDAs
Regulations at 21 CFR Part 320 address the requirements for bioavailability (BA) and BE data for approval of drug applications and supplemental applications. Provision for waivers of
in vivo
BA/BE studies (biowaivers) under certain conditions is provided at 21 CFR 320.22. This guidance explains when biowaivers can be requested for IR solid oral dosage forms based on an approach termed the Biopharmaceutics Classification System (BCS).
